药物性牙龈增生牙周非手术治疗的疗效观察

目的 评价单纯牙周非手术治疗对钙拮抗荆类药物导致的牙龈增生的临床疗效.方法 选取钙拮抗剂类药物导致的牙龈增生患者18例,男11例,女7例,在未停药的情况下进行牙周非手术治疗,在牙周非手术治疗前和治疗后1个月、3个月、6个月记录牙龈增生指数、茵斑指数、出血指数和探诊深度并与初诊时对照观察疗效.结果 牙周非手术治疗1个月后与基线相比,探诊深度、出血指数和牙龈增生指数出现了较明显的改善.经统计学检验有显著差异(P<0.01).茵斑指数无显著差异(P>0.05).牙周非手术治疗3个月、6个月后与基线相比牙龈增生指数、茼斑指数、出血指数和探诊深度均有显著性差异(P<0.05或P相似文献   

牙周基础治疗对药物性牙龈增生疗效的纵向观察

目的评价单纯牙周基础治疗对钙拮抗荆类药物导致的牙龈增生的治疗效果。方法选取钙拮抗荆类药物导致的牙龈增生患者13例，男8例，女5例，其中6例进行纵向观察，，在未停药的情况下进行牙周基础治疗，在治疗前和龈下刮治后1个月、3个月、6．5～29个月后记录牙龈增生指数、茵斑指数、出血指数和探诊深度。6名患者完成了纵向观察。结果在纵向观察期间，牙龈增生逐步减轻。在153个增生位点中，龈下刮治1个月后有69个位点痊愈，其中包括17个位点从2度、3度增生变为痊愈。3个月后痊愈的位点为105个，从2度、3度牙龈增生变为痊愈的位点数上升到41个。半年以上痊愈的位点数为122个，从2度、3度牙龈增生变为痊愈的位点数达50个。结论牙周基础治疗可改善钙拮抗剂药物引起牙龈增生的程度，其效果至少可保持半年以上。     

一氧化二氮吸入对药物性牙龈增生合并高血压患者牙周基础治疗影响的临床研究

目的:比较高血压患者一氧化二氮吸入和传统牙周基础治疗时的疼痛评分及血压状况差异.方法:本研究为随机对照临床试验.纳入药物性牙龈增生患者40例,其中36例完成了临床检查和治疗.36名患者在牙周探诊时分为2组(n =18),A组在一氧化二氮吸入下进行,B组在无麻醉下进行;4周后2组交换麻醉方式,比较2组临床指标、VAS评分...     

单纯牙周基础治疗对苯妥英钠所致药物性牙龈增生疗效评价

目的 评价单纯牙周基础治疗对苯妥英钠（PHT）所致药物性牙龈增生的治疗效果。方法 选择佛山市禅城区向阳医院·禅城区口腔医院2011年1月至2013年6月因服用PHT导致牙龈增生的患者16例,在不停药亦不换药的情况下行牙周基础治疗,并于治疗前及治疗后1、3、6个月进行牙龈增生指数（GHI）、菌斑指数（PLI）、龈沟出血指数（SBI）、探诊深度（PD）等临床指标检查。结果 单纯牙周基础治疗后1、3、6个月的GHI、PLI、SBI、PD各项临床指标逐步改善,牙龈炎症逐步减轻,牙龈增生状况持续好转;与治疗前基线相比,差异均有统计学意义（均P < 0.05）。结论 单纯牙周基础治疗对PHT所致药物性牙龈增生有效。     

定期牙周洁治对药物性牙龈增生术后复发的影响

目的 观察定期进行牙周洁治对使用环胞素A导致的牙龈增生且已行牙龈切除术的患者,术后复发情况的影响.方法 选取环胞素A导致的牙龈增生并行牙龈切除术的患者10例,男4例,女6例,在未停药的情况下定期复查.患者按复诊情况分为2组:第1组患者5人,每3个月复诊,给予牙周洁治;第2组患者5人,未能按时复诊,未予治疗,2组患者分别于半年、1年、＞1.5年记录牙龈增生指数、菌斑指数、牙石指数、出血指数和探诊深度.结果 半年时,2组牙龈增生发生率无显著性差异(P＞0.05),1年和＞1.5年时,第2组较第1组牙龈增生复发位点及复发率明显增高,有显著性差异(P＜0.01).结论 定期牙周洁治对于预防和减轻环胞素A导致的牙龈增生术后复发疗效明显.     

牙周干预对环孢菌素A相关牙龈增生的预防效果观察

目的评价肾移植术前牙周基础治疗对环孢菌素A相关的牙龈增生的预防效果。方法选取即将行肾移植术且拟用环孢菌素A作为免疫抑制剂的患者20名,随机分为牙周干预组（A组）和对照组（B组）,在平衡了年龄、性别等干扰因素的前提下,记录被研究者移植术前及术后3个月、6个月、12个月时的牙周指标。结果两组的牙周指标在肾移植术前比较差异无统计学意义（P〉0.05）;在观察期间,我们发现A组的PLI、SBI、PD指数在3、6、12个月与0个月比较有所下降,且差异有统计学意义（P〈0.05）,GHI指数随着时间推移均数有所升高,但各时间点之间差异并无统计学意义（P〉0.05）;B组的PLI、SBI、PD、GHI逐渐升高,且差异均有统计学意义（P〈0.05）。结论牙周感染可能是肾移植术后环孢菌素A相关的牙龈增生的原因之一,术前进行牙周基础治疗对环孢菌素A相关的牙龈增生的发生有一定的预防作用。     

药物性牙龈增生

牙龈增生可由多种药物引起，本文对三类药物引起牙龈增生的临床表现、组织学特征和致病机理进行了探讨。     

牙周非手术治疗对硝苯地平导致的老年人牙龈增生的疗效观察

目的:评价牙周非手术治疗对硝苯地平导致的老年人牙龈增生的治疗效果。方法:选取硝苯地平导致的牙龈增生患者18例,在基线和牙周非手术治疗后1个月、3个月、6个月、12个月分别记录菌斑指数、探诊深度、出血指数和牙龈增生指数。18例患者共13例完成了12个月的观察。结果:在观察期间,各指数持续改善(P<0.05),牙龈炎症持续减轻,牙龈增生状况明显改善。结论:牙周非手术治疗可改善硝苯地平引起的老年人牙龈增生的程度。     

米诺环素对药物性牙龈增生辅助治疗的疗效观察

药物性牙龈增生影响菌斑控制,加重牙龈的炎症.米诺环素用于辅助治疗慢性牙周炎的易复发或顽固的牙周袋,改善由于牙龈增生而口腔卫生不易维护的牙龈环境.本文探讨应用米诺环素软膏联合刮治和根面平整治疗钙拮抗剂诱导牙龈增生的疗效.     

���ܻ������ƶԸ��׿�������������������Ч�۲�

目的    观察牙周基础治疗对钙拮抗剂导致牙龈增生的治疗效果。方法    选取2006年6月至2009年3月在沈阳市口腔医院牙周科就诊,因高血压病服用钙拮抗剂导致牙龈增生的患者16例,在不更换药物或未停药的情况下进行牙周基础治疗,在治疗前基线和治疗后1、3、6个月时记录牙龈增生指数（GO）、菌斑指数（PIL）、龈沟出血指数（SBI）和探诊深度（PD）。结果    在观察期间,各指数持续改善（P < 0.01）,牙龈炎症持续减轻,牙龈增生状况明显改善。结论    牙周基础治疗对钙拮抗剂导致的牙龈增生有效,这为不能换药或停药的高血压患者提供了较合理的治疗方法。     

���̶�ҩ���������������ܷ���������Ӱ����о�

目的评价吸烟与非吸烟药物性牙龈增生患者单纯牙周非手术治疗1个月后的临床疗效。方法2007年3月至2007年12月收集河北省人民医院口腔科钙拮抗剂类药物导致的牙龈增生男性患者20例,其中吸烟组9例,非吸烟组11例,两组患者基线时的临床参数具有可比性。观察的牙龈增生牙齿,探诊深度5~7mm,吸烟组78个位点,非吸烟组80个位点。在未停药的情况下进行牙周非手术治疗,观察这些位点在治疗前、后1个月菌斑指数(PLI)、探诊深度(PD)、附着丧失(AL)、牙龈增生指数(HI)和出血指数(BI)的变化。结果治疗前两组PLI、BI、PD、AL以及HI差异无统计学意义,牙周非手术治疗1个月后,两组临床指标均有明显改善,吸烟组改善程度明显低于非吸烟组,但只有PD、PLI和HI的变化有统计学意义(P<0.05),AL和BI变化无统计学意义(P>0.05)。结论药物性牙龈增生患者,牙周非手术治疗效果吸烟者差于非吸烟者。     

Risk factors for drug-induced gingival overgrowth

Background/Aims: Drug‐induced gingival overgrowth remains a significant problem for the periodontologist. Many patients medicated with the drugs implicated in this unwanted effect experience significant, recurrent gingival problems that require repeated surgical excisions. In this review, we attempt to identify and quantify the various “risk factors” associated with both the development and expression of the drug‐induced gingival changes. Method: The risk factors appraised include age, sex, drug variables, concomitant medication, periodontal variables and genetic factors. Elucidation of such factors may help to identify “at risk patients” and then develop appropriate treatment strategies. Results: Of the factors identified, the only one that can be affected by the periodontologist is the patents' periodontal condition. However, drug variables and concomitant medication do impact upon the expression of gingival overgrowth. Conclusion: The identificatioin of risk factors associated with both the prevalence and severity of drug‐induced gingival overgrowth is important for all parties involved with this unwanted effect. Both periodontologist and patient have an important rôle to play in improving oral hygiene and gingival health. Likewise, there is always an opportinity to establish a close liaison between the patient's physician and the periodontologist to try and identify alternative drug regimens that can help reduce the impact of this unwanted effect.     

Amlodipine-induced gingival overgrowth: periodontal responses to stopping and restarting the drug

A case history of a woman with gingival overgrowth (GO) induced by amlodipine is presented. A 49-year-old Japanese woman, who was taking amlodipine, had gingival overgrowth and swelling on examination. No specific periodontal treatment was provided to the patient for the GO; however, the amlodipine was replaced with an ACE inhibitor after consultation with her medical practitioner. Within two months, the suspension of amlodipine resulted in a significant improvement in her periodontal condition. Failure to control the hypertension caused the physician to re-prescribe amlodipine. After three months, the gingival overgrowth returned; however, its severity was less when compared with the original periodontal condition, due to reduction in drug dose and periodontal therapy. This experience suggests that temporary suspension of a drug which can induce GO can improve the periodontal condition without the aid of surgical treatment.     

The pathogenesis of drug-induced gingival overgrowth

Abstract Gingival overgrowth is a well-documented unwanted effect, associated with phenytoin, cyclosporin. and the calcium channel blockers. The pathogenesis of drug-induced gingival overgrowth is uncertain, and there appears to be no unifying hypothesis that links together the 3 commonly implicated drugs. In this review, we consider a multifactorial model which expands on the interaction between drug and/or metabolite, with the gingival fibroblasts. Factors which impact upon this model include age. genetic predisposition, pharmacokinetic variables, plaque-induced inflammatory and immunological changes and activation of growth factors. Of these, genetic factors which give rise to fibroblast heterogeneity, gingival inflammation, and pharmacokinetic variables appear to be significant in the expression of gingival overgrowth, A more thorough understanding of the pathogenesis of this unwanted effect will hopefully elucidate appropriate mechanisms for its control.     

Photographic scoring of gingival overgrowth

BACKGROUND: A wide range of methods have been employed to determine the severity of gingival overgrowth resulting in uncertainty regarding the prevalence of the side-effect. There is no simple, non-invasive, objective, blind method for assessing gingival overgrowth. AIM: This article aims to describe a method which is suitable for use in large-scale population studies. MATERIALS AND METHODS: Photographs were taken of the anterior, buccal gingivae and teeth of 925 patients medicated with calcium channel blockers. In addition, each patient was ascribed a clinical gingival overgrowth score. 100 patients had repeat photographs, and a further 10 patients had alginate impressions taken. The models were scored for severity of gingival overgrowth using a described technique. The slides were scored using a modification of this technique. RESULTS: When photographic and study model scores were compared, photographic scores were consistently higher, and as a result, a photographic score of 38.6% was considered to represent a significant overgrowth. There was good agreement between clinically determined scores and photographic scores (kappa=0.71). CONCLUSIONS: The results indicate that this method is suitable for large-scale population studies where it also has the advantage of providing a continuous scale of gingival changes for subsequent statistical analysis.